Compare NAMS & FCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NAMS | FCN |
|---|---|---|
| Founded | 2019 | 1982 |
| Country | Netherlands | United States |
| Employees | 100 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 5.0B |
| IPO Year | N/A | 1996 |
| Metric | NAMS | FCN |
|---|---|---|
| Price | $33.92 | $153.44 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 1 |
| Target Price | $46.75 | ★ $165.00 |
| AVG Volume (30 Days) | ★ 1.4M | 493.4K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.51 |
| EPS | N/A | ★ 1.90 |
| Revenue | N/A | ★ $3,788,857,000.00 |
| Revenue This Year | $17.96 | $7.39 |
| Revenue Next Year | $540.65 | $7.10 |
| P/E Ratio | ★ N/A | $75.93 |
| Revenue Growth | N/A | ★ 2.44 |
| 52 Week Low | $16.79 | $140.84 |
| 52 Week High | $42.21 | $189.30 |
| Indicator | NAMS | FCN |
|---|---|---|
| Relative Strength Index (RSI) | 51.22 | 38.07 |
| Support Level | $34.05 | N/A |
| Resistance Level | $37.25 | $168.20 |
| Average True Range (ATR) | 2.29 | 8.42 |
| MACD | 0.36 | -2.57 |
| Stochastic Oscillator | 43.17 | 29.10 |
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
FTI Consulting Inc is a firm that generates its sales by providing professional business advisory services to customers. The company operates through five segments, namely corporate finance, forensic and litigation consulting, economic consulting, technology, and strategic communications. The company generates the majority of its revenue from the Corporate finance segment. Customers of the company come from a wide array of sectors, including construction, energy and power, environmental, financial institutions, healthcare and life science, insurance, real estate and infrastructure, retail and consumer products, telecom, media, and technology. The majority of the company's revenue is derived from serving customers in the United States.